Equillium to Present Translational Data on Itolizumab for Acute Graft-Versus-Host Disease at 61st American Society of Hematology (ASH) Annual Meeting and Exposition

San Diego Biotechnology Network
San Diego Biotechnology Network
Equillium to Present Translational Data on Itolizumab for Acute Graft-Versus-Host Disease at 61st American Society of Hematology (ASH) Annual Meeting and Exposition
Loading
/

LA JOLLA, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced that data supporting the role of the CD6-ALCAM pathway as a relevant target for patients with acute graft-versus-host disease (aGVHD) along with details of the EQUATE Phase 1b/2 trial design will be presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition being held from December 7-10, 2019 in Orlando, Florida.??